What is HC Wainwright’s Estimate for DBVT Q2 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for DBV Technologies in a report released on Monday, May 5th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.28) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.31) EPS and FY2029 earnings at $0.37 EPS.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $0.51 million during the quarter.

Other equities research analysts have also recently issued reports about the company. JMP Securities increased their price objective on DBV Technologies from $10.00 to $15.00 and gave the company a “market outperform” rating in a research report on Thursday, May 1st. StockNews.com assumed coverage on shares of DBV Technologies in a report on Thursday, May 1st. They issued a “hold” rating for the company.

DBV Technologies Stock Up 3.4 %

Shares of NASDAQ:DBVT opened at $9.25 on Tuesday. The company has a market cap of $253.36 million, a price-to-earnings ratio of -2.06 and a beta of -0.66. The business has a 50 day moving average price of $6.47 and a 200 day moving average price of $4.71. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.09.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.